https://www.biocentury.com/article/656520/third-death-from-a-sarepta-gene-therapy

This Edition
[]BioCenturyBioCentury
 
[                    ]
[]BioCenturyBioCentury
[]YouTubeYouTube[]LinkedInLinkedIn[]XX[]RSSRSS
ARTICLE | Product Development

Third death from a Sarepta gene therapy

Patient was in trial of the company's limb-girdle muscular dystrophy
gene therapy

By Steve Usdin, Washington Editor
July 17, 2025 11:51 PM UTC
[yH5BAEAAAA][cmd87jhcwn]

A third patient, a 51 year-old in a Phase I study of SRP-9004 for
Limb-Girdle muscular dystrophy Type 2E, has died from a Sarepta gene
therapy.

Like two deaths associated with the company's Duchenne muscular
dystrophy gene therapy, Elevidys delandistrogene moxeparvovec, the
most recent death was caused by acute liver toxicity, Sarepta
Therapeutics Inc. (NASDAQ:SRPT) spokesperson Tracy Sorrentino told
BioCentury. ...

BCIQ Company Profiles

Sarepta Therapeutics Inc.

BCIQ Company Profiles

Sarepta Therapeutics Inc.

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Cookie Policy
California Privacy Rights
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
[]YouTubeYouTube[]LinkedInLinkedIn[]XX[]RSSRSS
[]BioCenturyBioCentury
(c) 2025 BioCentury Inc. All Rights Reserved.
Copyright (c) 2025 BioCentury Inc. All Rights Reserved.
[]YouTubeYouTube[]LinkedInLinkedIn[]XX[]RSSRSS